OnKure Therapeutics, Inc. (OKUR)
| Market Cap | 164.41M +445.7% |
| Revenue (ttm) | n/a |
| Net Income | -58.75M |
| EPS | -4.33 |
| Shares Out | 40.40M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 295,154 |
| Open | 3.600 |
| Previous Close | 3.560 |
| Day's Range | 3.580 - 4.200 |
| 52-Week Range | 1.910 - 5.380 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 20.20 (+396.31%) |
| Earnings Date | May 5, 2026 |
About OKUR
OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3-kinase alpha (PI3Kα) harboring the H1047R mutation that is in Phase 1 clinical trial for the treatment of solid tumors, including breast cancer. The company was founded in 2011 and is headquartered in Boulder, Colorado.
Financial Performance
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for OKUR stock is "Strong Buy." The 12-month stock price target is $20.2, which is an increase of 396.31% from the latest price.
News
OnKure Therapeutics downgraded to Hold from Buy at JonesResearch
JonesResearch downgraded OnKure Therapeutics (OKUR) to Hold from Buy after the company recently announced the discontinuation of their OKI-219, being developed for metastatic/advanced breast cancer, a...
OnKure Therapeutics Reports First Quarter 2026 Financial Results
-- Announced nomination of OKI-355, a next-generation PI3Kα pan-mutant selective inhibitor candidate, in vascular anomalies -- Initiated a discovery research program to expand the company's pipeline i...
OnKure Therapeutics Quarterly report: Q1 2026
OnKure Therapeutics has published its Q1 2026 quarterly earnings report on May 5, 2026.
OnKure Therapeutics Earnings release: Q1 2026
OnKure Therapeutics released its Q1 2026 earnings on May 5, 2026, summarizing the period's financial results.
OnKure Therapeutics files to sell 36.14M shares of Class A common for holders
16:05 EDT OnKure Therapeutics (OKUR) files to sell 36.14M shares of Class A common for holders
OnKure Therapeutics Registration statement: Registration filing
OnKure Therapeutics filed a registration statement on April 24, 2026, providing details about a securities offering with the SEC.
OnKure Therapeutics Slides: Corporate presentation
OnKure Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on April 24, 2026.
OnKure Therapeutics Proxy statement: Proxy filing
OnKure Therapeutics filed a proxy statement on April 21, 2026, providing details for shareholder voting and corporate governance matters.
OnKure Therapeutics Proxy statement: Proxy filing
OnKure Therapeutics filed a proxy statement on April 21, 2026, providing details for shareholder voting and corporate governance matters.
OnKure Therapeutics to sell 26.713M shares at $4.15 in private placement
OnKure Therapeutics (OKUR) announced that it has entered into a securities purchase agreement for a private placement with certain institutional and accredited healthcare investors, raising gross proc...
OnKure Therapeutics Announces Oversubscribed $150 Million Private Placement to Advance Next-Generation PI3Kα Pan-Mutant Selective Inhibitor Candidates in Breast Cancer and Vascular Anomalies
-- Financing led by Access Biotechnology with participation from new and existing investors -- Financing to support advancement of two next-generation PI3Kα pan-mutant inhibitors for breast cancer and...
OnKure Therapeutics price target lowered to $27 from $34 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on OnKure Therapeutics (OKUR) to $27 from $34 and keeps a Buy rating on the shares post the Q4 report. The firm dropped…
OnKure Therapeutics reports Q4 EPS (99c), consensus ($1.15)
“We are pleased with the continued progress across our PI3Kalpha-focused pipeline, including the steady execution of the PIKture-01 trial of OKI-219. We look forward to sharing updated data from this…
OnKure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
-- Data from the ongoing PIKture-01 trial is expected to be announced in March 2026 ; continued enrollment in breast cancer triplet combinations
OnKure Therapeutics Earnings release: Q4 2025
OnKure Therapeutics released its Q4 2025 earnings on March 12, 2026, summarizing the period's financial results.
OnKure Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference
Key clinical data for OKI-219 in monotherapy, doublet, and triplet regimens are expected in Q1 2026, with a focus on demonstrating high tolerability and efficacy versus competitors. The pipeline includes a unique HER2-positive triplet and a pan-mutant program with strong selectivity benchmarks.
OnKure Therapeutics Transcript: Stifel 2025 Healthcare Conference
The presentation highlighted progress on highly selective PI3K alpha inhibitors, with OKI-219 advancing through monotherapy, doublet, and triplet studies in breast cancer. Key data on efficacy, safety, and combinability are expected in Q1 2026, guiding future development and competitive positioning.
OnKure Therapeutics Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference
OKI-219, a highly selective PI3K alpha inhibitor, is advancing through monotherapy, doublet, and triplet clinical studies, with key data expected in Q1 2026. The compound's strong selectivity, CNS penetration, and favorable tolerability profile position it to compete in front-line breast cancer settings.
OnKure Therapeutics files $200M mixed securities shelf
17:09 EST OnKure Therapeutics (OKUR) files $200M mixed securities shelf
OnKure Therapeutics reports Q3 EPS ($1.09), consensus ($1.20)
“We have made steady progress advancing our lead clinical development program, OKI-219, and are committed to leading the advancement of selective PI3Kalpha inhibitors for the treatment of patients wit...
OnKure Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Business Update
-- First patients dosed in triplet expansion arms of the PIKture-01 trial evaluating OKI-219 in combination with fulvestrant and ribociclib, and in combination with trastuzumab and tucatinib in patien...
OnKure Therapeutics Earnings release: Q3 2025
OnKure Therapeutics released its Q3 2025 earnings on November 6, 2025, summarizing the period's financial results.
OnKure Therapeutics Slides: Investor Presentation
OnKure Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on November 5, 2025.
OnKure Therapeutics to Participate in Upcoming Investor Conferences
BOULDER, Colo., Nov. 04, 2025 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (Nasdaq: OKUR), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines, today an...
OnKure Therapeutics reports Q2 EPS ($1.14), consensus ($1.25)
“We are encouraged by the continued progress in the development of our lead asset, OKI-219, as we have completed the enrollment of the single agent and the fulvestrant combination arms…